Lonza

Now we can help your CMC team overcome the challenge of rising API complexity… Contact us to learn more about Lonza’s AI-Enabled Route Scouting Service. https://lnkd.in/e6xiUpZU #RouteScouting #API #SmallMolecules #WeWorkAsOne

"The complexity of drugs and their delivery has been increasing over the past few decades. Combined with a growing prevalence of chronic illnesses, this market evolution is putting more pressure on pharmaceutical manufacturers to develop novel therapies that might also have unique formulation needs.” Peter Droc, Head of Drug Product Services at Lonza, recently shared his thoughts on the solutions to increasingly complex formulation needs, and how these can ensure quality and patient safety, while also decreasing time-to-market. Belinda Holdsworth, Strategic Growth Project Lead for DPS at Lonza, also emphasized how a robust visual inspection process which utilizes AI and automated robotics can greatly enhance process timelines. Read the full article here: https://lnkd.in/eds3Xnkw #AHealthierWorld #DrugProduct #LonzaDPS

Join us tomorrow to discover the commercial capabilities of the Lonza Small Molecules network and dive into a risk-based approach for process qualification of amorphous solid dispersions made by spray drying. In this insightful session, our experts will discuss the integration of process design and qualification into the broader process validation strategy. You'll learn how small-scale experiments can optimize drug substance usage and mitigate risks during the process qualification stage. We’ll also explore elements of product design, focusing on robust processes with built-in manufacturing flexibility. 💡 Real-world case studies will illustrate in-process hold times at full scale, providing practical examples of our methodologies in action. Register here: https://lnkd.in/dAM4k_Qe #LonzaSM

Kathrin joined Lonza in 2021, and works as an MSAT Expert for Drug Product Services at our site in Stein, Switzerland. "The daily dynamics of our work are determined by the diverse scientific knowledge and industry experiences that each team member contributes. Working at Lonza is an exciting journey as we continually realign with current market and customer needs. It offers me a variety of professional and personal opportunities to grow in my current role and if desired explore alternative career paths within the company." Read Kathrin's full story: https://lnkd.in/dCeKcrNE #AMeaningfulDifference #CareerGrowth #Opportunities #PharmaceuticalManufacturing

A recent webinar highlighted a really important collaboration between our team in Bend and scientists at the Access to Advanced Health Institute (AAHI) in Seattle. They’ve been looking to develop a nasal dry powder formulation of a vaccine for tuberculosis. As such a vaccine would be shelf-stable, it could be an incredibly important tool for preventing infection in developing countries, where cold-chain distribution of vaccines is a challenge. Sana Hosseini, Ph.D. and Kimberly Shepard from Bend gave the webinar alongside AAHI’s John Chen. They explained how spray drying – a key technique used by Lonza for making dry powders – can be used to make the formulation, and how it behaves within a nasal inhalation device. The webinar is now available to watch on demand, so if you missed it live, you can now catch up with it here. https://lnkd.in/eUFewpmN #LonzaSM #dpi #inhalation

Join one of our #microbial experts next week for an insightful webinar on the ups and downs of bioprocess scale-up from the perspective of a leading CDMO. 📅 Monday, 17 June 🕝 11am EDT / 5pm CET Register today: https://lnkd.in/dkGzfCw9 #Lonza #Biologics

"The current mRNA testing setup is not sustainable for meeting future regulatory expectations. This modality is continuing to become the lead technology for manufacturing seasonal vaccines and oncology therapeutics. The availability of rapid and reliable sequencing will be mandatory on that journey," says Torsten Schmidt, Head of mRNA at Lonza. The Medicine Maker recently interviewed Torsten and Chris Brown, Vice President of Strategic Programmes at Oxford Nanopore about how analytical techniques are crucial to further development in mRNA. Read the full interview here: https://lnkd.in/dYEywCUN

We’re looking forward to seeing you at the 28th ESACT Meeting in Edinburgh, UK. Join us for an exciting educational session on Industry Perspectives on Cell Line Development. We’re gathering experts in the bioproduction field to take a deeper look at a therapeutic protein’s journey from discovery to commercial supply. We will look specifically at each stage of the process from DNA design to clone selection, to see how such workflows are optimised. See you there and at our booth #38 📅 Day 3 | Tuesday 25th June 🕝 12:40 – 13.40 📍 Room Lammermuir 2 #LonzaExpressionSystems #LonzaInYourLab #biotechnology #celllinedevelopment #ESACT2024

A well-understood risk-based manufacturing process in drug development is critical to success. From support process qualification for amorphous solid dispersions by spray drying to process validation strategies and small-scale experimentation – our latest webinar is designed to guide industry directors, CMC leads, development engineers and technical operators toward better development outcomes. Join us on Thursday, June 20, 11:00am EDT to discover the commercial capabilities of using a CDMO, the essential attributes of SDD formulations, and how to achieve reduced risk and material use. To register your place, visit: https://lnkd.in/dAM4k_Qe #LonzaSM #WeWorkAsOne

#BIO2024 is in full swing and we're here at booth 5335, ready to talk about your biologics needs. #LonzaBio #pharma #biotechnology #ThePeoplePoweringBiologics